{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:28:20Z","timestamp":1761895700545,"version":"3.44.0"},"reference-count":33,"publisher":"BMJ","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dis Child Fetal Neonatal Ed"],"accepted":{"date-parts":[[2013,6,4]]},"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:p>While current management of retinopathy of prematurity (ROP) is well evidenced, the recent Neonatal Oxygenation Prospective Meta-analysis (NeoPROM) oxygen therapy trials, and the Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP) trial of intravitreal injection bevacizumab, have reopened debate on optimal management. Early postnatal manipulation of oxygen therapy, nutrition and serum IGF 1 levels may improve early retinal blood vessel development and prevent later severe ROP. While the use of intravitreal injections of antivascular endothelial growth factor (VEGF) agents may appear to be an attractive alternative to laser ablation of the peripheral retina, caution is needed. The optimal choice of agent and dose remain unknown, and suppression of serum VEGF levels might interfere with normal angiogenesis processes in developing tissues. There is a pressing need for good Phase 1 studies of these agents, and safety trials.<\/jats:p>","DOI":"10.1136\/archdischild-2013-303933","type":"journal-article","created":{"date-parts":[[2013,6,29]],"date-time":"2013-06-29T00:17:22Z","timestamp":1372465042000},"page":"F454-F456","source":"Crossref","is-referenced-by-count":19,"title":["Management of retinopathy of prematurity"],"prefix":"10.1136","volume":"98","author":[{"given":"Brian William","family":"Fleck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2013,6,27]]},"reference":[{"key":"2025090221214211000_98.5.F454.1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2008.128"},{"key":"2025090221214211000_98.5.F454.2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-2749"},{"key":"2025090221214211000_98.5.F454.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208506"},{"key":"2025090221214211000_98.5.F454.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374"},{"key":"2025090221214211000_98.5.F454.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2007.11.009"},{"key":"2025090221214211000_98.5.F454.6","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.12.1684"},{"key":"2025090221214211000_98.5.F454.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2007.11.008"},{"key":"2025090221214211000_98.5.F454.8","first-page":"1201","article-title":"The effect of oxygen on vasoformative cell division. Evidence that \u2018physiological hypoxia\u2019 is the stimulus for normal retinal vasculogenesis","volume":"36","author":"Chan-Ling","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025090221214211000_98.5.F454.9","doi-asserted-by":"publisher","DOI":"10.1542\/peds.112.5.1016"},{"key":"2025090221214211000_98.5.F454.10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.101113998"},{"key":"2025090221214211000_98.5.F454.11","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.234"},{"key":"2025090221214211000_98.5.F454.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.12.023"},{"key":"2025090221214211000_98.5.F454.13","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.7.991"},{"key":"2025090221214211000_98.5.F454.14","doi-asserted-by":"publisher","DOI":"10.1542\/peds.105.2.295"},{"key":"2025090221214211000_98.5.F454.15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/archopht.1956.00930040489001","article-title":"Retrolental fibroplasia; cooperative study of retrolental fibroplasia and the use of oxygen","volume":"56","author":"Kinsey","year":"1956","journal-title":"AMA Arch Ophthalmol"},{"key":"2025090221214211000_98.5.F454.16","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S0140-6736(73)92610-X","article-title":"Cost of preventing retrolental fibroplasia?","volume":"2","author":"Cross","year":"1973","journal-title":"Lancet"},{"key":"2025090221214211000_98.5.F454.17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2431-11-6","article-title":"NeOProM: Neonatal Oxygenation Prospective Meta-analysis Collaboration study protocol","volume":"11","author":"Askie","year":"2011","journal-title":"BMC Pediatr"},{"key":"2025090221214211000_98.5.F454.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1101319"},{"key":"2025090221214211000_98.5.F454.19","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.124.12.1711"},{"key":"2025090221214211000_98.5.F454.20","doi-asserted-by":"crossref","unstructured":"Can E Bulbul A Uslu S . Effects of aggressive parenteral nutrition on growth and clinical outcome in preterm infants. Pediatr Int 2012.","DOI":"10.1111\/j.1442-200X.2012.03713.x"},{"key":"2025090221214211000_98.5.F454.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2007.04.068"},{"key":"2025090221214211000_98.5.F454.22","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2012.146"},{"key":"2025090221214211000_98.5.F454.23","doi-asserted-by":"publisher","DOI":"10.1203\/PDR.0b013e31819d9e8c"},{"key":"2025090221214211000_98.5.F454.24","doi-asserted-by":"publisher","DOI":"10.1038\/nm1591"},{"key":"2025090221214211000_98.5.F454.25","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2011-300276"},{"key":"2025090221214211000_98.5.F454.26","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2012.592"},{"key":"2025090221214211000_98.5.F454.27","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-302276"},{"key":"2025090221214211000_98.5.F454.28","doi-asserted-by":"crossref","unstructured":"Mintz-Hittner HA . Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial. Eur J Ophthalmol 2012;22:685\u20136.","DOI":"10.5301\/ejo.5000176"},{"key":"2025090221214211000_98.5.F454.29","doi-asserted-by":"publisher","DOI":"10.2174\/187152811798104872"},{"key":"2025090221214211000_98.5.F454.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.04.015"},{"key":"2025090221214211000_98.5.F454.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.07.005"},{"key":"2025090221214211000_98.5.F454.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2012.02469.x"},{"key":"2025090221214211000_98.5.F454.33","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9516"}],"container-title":["Archives of Disease in Childhood - Fetal and Neonatal Edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2013-303933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T04:21:53Z","timestamp":1756873313000},"score":1,"resource":{"primary":{"URL":"https:\/\/fn.bmj.com\/lookup\/doi\/10.1136\/archdischild-2013-303933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,27]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,8,18]]},"published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1136\/archdischild-2013-303933"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2013-303933","relation":{},"ISSN":["1359-2998","1468-2052"],"issn-type":[{"type":"print","value":"1359-2998"},{"type":"electronic","value":"1468-2052"}],"subject":[],"published":{"date-parts":[[2013,6,27]]}}}